Is it safe to use GLP‑1 receptor agonists (e.g., exenatide, liraglutide, semaglutide) while breastfeeding?

GLP-1 Receptor Agonists and Breastfeeding

GLP-1 receptor agonists should be avoided during breastfeeding due to insufficient safety data, though emerging evidence suggests minimal transfer into breast milk.

Current Evidence on Milk Transfer

The most recent and highest quality study directly addressing this question found that semaglutide was undetectable in human milk samples from eight lactating women at 0,12, and 24 hours post-administration 1. Even using a worst-case scenario calculation with the lower limit of quantification, the relative infant dose (RID) was only 1.26%—well below the standard 10% safety threshold considered acceptable for breastfeeding 1.

Animal data from FDA labeling shows liraglutide was present in rat milk at approximately 50% of maternal plasma concentrations 2, though this may not translate directly to humans given species differences in milk composition and drug handling.

FDA Labeling Guidance

The official FDA labels for both major GLP-1 receptor agonists state:

• Liraglutide (Victoza): "There are no data on the presence of VICTOZA in human milk, the effects on the breastfed infant, or the effects on milk production" 2

• Semaglutide (Ozempic): Similar language indicating lack of human lactation data 3

Both labels recommend considering "developmental and health benefits of breastfeeding...along with the mother's clinical need" and "any potential adverse effects on the breastfed infant" 2.

Clinical Recommendation

Until more robust human safety data become available, GLP-1 receptor agonists should not be used during breastfeeding. Alternative diabetes or weight management strategies compatible with lactation should be prioritized 4.

Key Considerations:

• Insufficient human data: Despite the encouraging semaglutide milk transfer study, this represents only 8 women with short-term sampling 1
• Unknown long-term effects: No data exist on infant neurodevelopment, growth, or metabolic outcomes with chronic exposure
• Maternal nutritional concerns: GLP-1 agonists reduce appetite and food intake, potentially compromising maternal nutrition and milk quality during the high metabolic demands of lactation
• Large molecular weight: As peptides with molecular weights >3,000 Da, GLP-1 agonists theoretically have limited milk transfer, but oral bioavailability in infants remains uncertain

Common Pitfalls to Avoid:

1. Don't assume safety based solely on molecular size—while large peptides typically transfer poorly into milk, the clinical significance of even small amounts in a developing infant is unknown
2. Don't extrapolate from pregnancy data—placental and mammary transfer mechanisms differ substantially
3. Consider the indication carefully—for type 2 diabetes, insulin is well-established as safe during breastfeeding; for obesity management, lifestyle modifications should be first-line during lactation

Alternative Approaches

For lactating women requiring glycemic control, insulin remains the gold standard with extensive safety data. For weight management, defer GLP-1 agonist therapy until after weaning when possible.